About this Journal Submit a Manuscript Table of Contents
Case Reports in Endocrinology
Volume 2011 (2011), Article ID 867475, 4 pages
http://dx.doi.org/10.1155/2011/867475
Case Report

Thyrotoxic Periodic Paralysis: Case Reports and an Up-to-Date Review of the Literature

1Department of Endocrinology, South London HealthCare NHS Trust, Orpington Hospital, Sevenoaks Road, Orpington BR6 9JU, UK
2Department of Endocrinology, Whittington NHS Trust Hospital, London N19 5NF, UK

Received 4 June 2011; Accepted 20 July 2011

Academic Editors: G. Aimaretti, K. Kasagi, L. Meyer, and W. V. Moore

Copyright © 2011 Abbi Lulsegged et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. J. Hsu, Y. F. Lin, T. Chau, J. T. Liou, S. W. Kuo, and S. H. Lin, “Electrocardiographic manifestations in patients with thyrotoxic periodic paralysis,” The American Journal of the Medical Sciences, vol. 326, no. 3, pp. 128–132, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. S. L. Venance, S. C. Cannon, D. Fialho et al., “The primary periodic paralyses: diagnosis, pathogenesis and treatment,” Brain, vol. 129, no. 1, pp. 8–17, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. T. Ai, Y. Fujiwara, K. Tsuji et al., “Novel KCNJ2 mutation in familial periodic paralysis with ventricular dysrhythmia,” Circulation, vol. 105, no. 22, pp. 2592–2594, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. C. W. Lu, J. H. Lin, Y. S. Rajawat et al., “Functional and clinical characterization of a mutation in KCNJ2 associated with Andersen-Tawil syndrome,” Journal of Medical Genetics, vol. 43, no. 8, pp. 653–659, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. A. J. McFadzean and R. Yeung, “Periodic paralysis complicating thyrotoxicosis in Chinese,” The British Medical Journal, vol. 1, no. 538, pp. 451–455, 1967. View at Scopus
  6. R. C. Reisin, O. Martinez, M. Moran et al., “Thyrotoxic periodic paralysis in caucasians. Report of 8 cases,” Neurologia, vol. 15, no. 6, pp. 222–225, 2000. View at Scopus
  7. C. Chatot-Henry, D. Smadja, R. Longhi, A. Brebion, and G. Sobesky, “Thyrotoxic periodic paralysis. Two news cases in black race patients,” Revue de Medecine Interne, vol. 21, no. 7, pp. 632–634, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. S. R. Mehta, A. Verma, H. Malhotra, and S. Mehta, “Normokalaemic periodic paralysis as the presenting manifestation of hyperthyroidism,” Journal of the Association of Physicians of India, vol. 38, no. 4, pp. 296–297, 1990. View at Scopus
  9. L. Lam, R. J. Nair, and L. Tingle, “Thyrotoxic periodic paralysis,” Proceedings (Baylor University. Medical Center), vol. 19, no. 2, pp. 126–129, 2006.
  10. L. Forrest and J. Platts, “Ecstasy-induced thyrotoxic periodic paralysis,” BMJ Case Reports, bcr0920092280, 2009. View at Publisher · View at Google Scholar
  11. M.-J. Hsieh, R.-K. Lyu, W.-N. Chang et al., “Hypokalemic thyrotoxic periodic paralysis: clinical characteristics and predictors of recurrent paralytic attacks,” The European Journal of Neurology, vol. 15, no. 6, pp. 559–564, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. S. Wongraoprasert, P. Buranasupkajorn, V. Sridama, and T. Snabboon, “Thyrotoxic periodic paralysis induced by pulse methylprednisolone,” Internal Medicine, vol. 46, no. 17, pp. 1431–1434, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Shulkin, B. R. Olson, and G. S. Levey, “Thyrotoxic periodic paralysis in a Latin-American taking acetazolamide,” The American Journal of the Medical Sciences, vol. 297, no. 5, pp. 337–338, 1989. View at Scopus
  14. S. Chaudhury, F. Ismail-Beigi, G. G. Gick, R. Levenson, and I. S. Edelman, “Effect of thyroid hormone on the abundance of Na,K-adenosine triphosphatase α-subunit messenger ribonucleic acid,” Molecular Endocrinology, vol. 1, no. 1, pp. 83–89, 1987. View at Scopus
  15. V. M. S. Oh, E. A. Taylor, S.-H. Yeo, and K.-O. Lee, “Cation transport across lymphocyte plasma membranes in euthyroid and thyrotoxic men with and without hypokalaemic periodic paralysis,” Clinical Science, vol. 78, no. 2, pp. 199–206, 1990. View at Scopus
  16. M. Guerra, A. Rodriguez del Castillo, E. Battaner, and M. Mas, “Androgens stimulate preoptic area Na+K+-ATPase activity in male rats,” Neuroscience Letters, vol. 78, no. 1, pp. 97–100, 1987. View at Scopus
  17. S. Soonthornpun, W. Setasuban, and A. Thamprasit, “Insulin resistance in subjects with a history of thyrotoxic periodic paralysis (TPP),” Clinical Endocrinology, vol. 70, no. 5, pp. 794–797, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. A. Chan, R. Shinde, C. C. Chow, C. S. Cockram, and R. Swaminathan, “Hyperinsulinaemia and Na+, K+-ATPase activity in thyrotoxic periodic paralysis,” Clinical Endocrinology, vol. 41, no. 2, pp. 213–216, 1994. View at Scopus
  19. A. W. Kung, “Clinical review: thyrotoxic periodic paralysis: a diagnostic challenge,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 7, pp. 2490–2495, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. S. H. Lin, P. Chu, C. J. Cheng, S. J. Chu, Y. J. Hung, and Y. F. Lin, “Early diagnosis of thyrotoxic periodic paralysis: spot urine calcium to phosphate ratio,” Critical Care Medicine, vol. 34, no. 12, pp. 2984–2989, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. M. J. Hannon, L. A. Behan, and A. Agha, “Thyrotoxic periodic paralysis due to excessive L-thyroxine replacement in a Caucasian man,” Annals of Clinical Biochemistry, vol. 46, no. 5, pp. 423–425, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. H.-K. Chou, Y.-T. Tsao, and S.-H. Lin, “An unusual cause of thyrotoxic periodic paralysis: triiodothyronine-containing weight reducing agents,” The American Journal of the Medical Sciences, vol. 337, no. 1, pp. 71–73, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. T. Pappa, L. Papanastasiou, A. Markou et al., “Thyrotoxic periodic paralysis as the first manifestation of a thyrotropin-secreting pituitary adenoma,” Hormones, vol. 9, no. 1, pp. 82–86, 2010. View at Scopus
  24. G. T. C. Ko, C. C. Chow, V. T. F. Yeung, H. H. L. Chan, J. K. Y. Li, and C. S. Cockram, “Thyrotoxic periodic paralysis in a Chinese population,” QJM, vol. 89, no. 6, pp. 463–468, 1996. View at Scopus
  25. C. Boccalandro, L. Lopez, F. Boccalandro, and V. Lavis, “Electrocardiographic changes in thyrotoxic periodic paralysis,” The American Journal of Cardiology, vol. 91, no. 6, pp. 775–777, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Miyashita, T. Monden, K. Yamamoto et al., “Ventricular fibrillation due to severe hypokalemia induced by steroid treatment in a patient with thyrotoxic periodic paralysis,” Internal Medicine, vol. 45, no. 1, pp. 11–13, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. S. A. Aldasouqi, S. A. Bokhari, P. M. Khan, and A. S. Al-Zahrani, “Thyrotoxic periodic paralysis in a Saudi patient complicated by life-threatening arrhythmia,” Saudi Medical Journal, vol. 30, no. 4, pp. 564–568, 2009. View at Scopus
  28. K. C. Lu, Y. J. Hsu, J. S. Chiu, Y. D. Hsu, and S. H. Lin, “Effects of potassium supplementation on the recovery of thyrotoxic periodic paralysis,” The American Journal of Emergency Medicine, vol. 22, no. 7, pp. 544–547, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. J. O. Levitt, “Practical aspects in the management of hypokalemic periodic paralysis,” Journal of Translational Medicine, vol. 6, article 18, 2008. View at Publisher · View at Google Scholar · View at PubMed
  30. H. Tassone, A. Moulin, and S. O. Henderson, “The pitfalls of potassium replacement in thyrotoxic periodic paralysis: a case report and review of the literature,” Journal of Emergency Medicine, vol. 26, no. 2, pp. 157–161, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. S. H. Lin and Y. F. Lin, “Propranolol rapidly reverses paralysis, hypokalemia, and hypophosphatemia in thyrotoxic periodic paralysis,” The American Journal of Kidney Diseases, vol. 37, no. 3, pp. 620–623, 2001. View at Scopus
  32. R. T. Yeung and T. F. Tse, “Thyrotoxic periodic paralysis: effect of propranolol,” The American Journal of Medicine, vol. 57, no. 4, pp. 584–590, 1974. View at Scopus
  33. S. Akar, A. Comlekci, M. Birlik et al., “Thyrotoxic periodic paralysis in a turkish male; the recurrence of the attack after radioiodine treatment,” Endocrine Journal, vol. 52, no. 1, pp. 149–151, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. D. P. Ryan, M. R. Dias da Silva, T. W. Soong et al., “Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis,” Cell, vol. 140, no. 1, pp. 88–98, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus